Michael Lahn

Employment

• iOnctura
  2019 - Present
• Incyte Biosciences International
  2015 - 2019
• AstraZeneca Pharmaceuticals LP
  2014 - 2015
• Eli Lilly and Co
  2000 - 2014

Education

• Johannes Gutenberg Universität Mainz

Projects & Funding

Projects & funding information is unavailable.

Publications (5)

• Approaches to overcome the current treatment plateau in immunotherapy
  European Journal of Cancer 2025 DOI: 10.1016/j.ejca.2025.115605
  +Save
• The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
  European Journal of Cancer 2024 DOI: 10.1016/j.ejca.2023.113501
  +Save
• Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib
  International Journal of Toxicology 2023 DOI: 10.1177/10915818231200419
  +Save
• Immunotherapy for brain metastases and primary brain tumors
  European Journal of Cancer 2023 DOI: 10.1016/j.ejca.2022.11.012
  +Save
• Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
  European Journal of Cancer 2021 DOI: 10.1016/j.ejca.2021.04.035
  +Save